Results 241 to 250 of about 58,085 (295)
Some of the next articles are maybe not open access.
Epitope‐spreading phenomena in dipeptidyl peptidase‐4 inhibitor‐associated bullous pemphigoid
British Journal of Dermatology, 2019Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid (DPP4i-BP) has been linked to a characteristic non-inflammatory BP phenotype and to the presence of autoantibodies directed against the midportion of BP180 ectodomain. However, DPP4i-BP cases
I. García-Díez, A. España, P. Iranzo
semanticscholar +1 more source
Renal outcomes with dipeptidyl peptidase-4 inhibitors
Diabetes & Metabolism, 2018Dipeptidyl peptidase-4 inhibitors (DPP-4is) are increasingly being used in the management of type 2 diabetes (T2D). The present review summarizes the current knowledge of the effects of DPP-4is on renal outcomes by analyzing the experimental preclinical data, the effects of DPP-4is on urinary albumin-creatinine ratios (UACRs) and estimated glomerular ...
Scheen, André, DELANAYE, Pierre
openaire +3 more sources
Pharmacology of Dipeptidyl Peptidase-4 Inhibitors
Drugs, 2011The dipeptidyl peptidase (DPP)-4 inhibitors, which enhance glucose-dependent insulin secretion from pancreatic β cells by preventing DPP-4-mediated degradation of endogenously released incretin hormones, represent a new therapeutic approach to the management of type 2 diabetes mellitus. The 'first-in-class' DPP-4 inhibitor, sitagliptin, was approved in
R. Baetta, A. Corsini
openaire +2 more sources
Dipeptidyl peptidase 4 inhibitor‐associated mucous membrane pemphigoid
The Journal of Dermatology, 2021AbstractDipeptidyl peptidase 4 inhibitors (DPP‐4i) are associated with an increased risk of developing bullous pemphigoid (BP) in patients with diabetes. Autoantibodies targeting epitopes on the processed BP180, 120‐kDa (LAD‐1), and 97‐kDa (LABD97) linear immunoglobulin (Ig)A dermatosis antigens are the major autoantibodies in DPP‐4i‐associated BP ...
Mei Suezawa +8 more
openaire +2 more sources
Dipeptidyl-Peptidase 4 (DPP4) Inhibitors
Highlights: Introduction Pharmacology Treatment Advantages/Disadvantages Therapeutic Considerations Monographs ...Kimberly C. McKeirnan +1 more
+4 more sources
Dipeptidyl peptidase-4 inhibitors
2016Dipeptidyl peptidase (DPP)-4 inhibitors inhibit the activity of the enzyme responsible for the initial rapid degradation of the incretin hormones, thereby enhancing their antihyperglycemic effects.
openaire +1 more source
Effect of dipeptidyl peptidase‐4 inhibitors on complement activation
Diabetes/Metabolism Research and Reviews, 2020AbstractBackgroundAdverse activation of the complement cascade in the innate immune system appears to be involved in development of vascular complications in diabetes. Dipeptidyl peptidase‐4 (DPP‐4) is a cell surface serine protease expressed in a variety of tissues.
Ingeborg T. Hoffmann‐Petersen +7 more
openaire +3 more sources
Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors
Clinical Pharmacokinetics, 2012Dipeptidyl peptidase-4 (DPP-4) inhibitors collectively comprise a presently unique form of disease management for persons with type 2 diabetes mellitus. The aim of this review is to compare the clinical pharmacokinetics of available DPP-4 inhibitors (alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin) for the purpose of identifying ...
Larry K, Golightly +2 more
openaire +2 more sources
Dipeptidyl Peptidase-4 Inhibitor Induced Angioedema - An Overlooked Adverse Drug Reaction?
Current Diabetes Reviews, 2017INTRODUCTION Angioedema is a potentially fatal adverse drug reaction of some medications, as swellings of the upper airways can cause death by asphyxiation.
S. Scott +4 more
semanticscholar +1 more source
Tolerability of Dipeptidyl Peptidase-4 Inhibitors: A Review
Clinical Therapeutics, 2011Oral glucose-lowering agents are used to treat patients with type 2 diabetes mellitus (T2DM). Most patients require multiple agents to maintain glycemic targets. Dipeptidyl peptidase-4 (DPP-4) inhibitors are administered as monotherapy and in combination therapy for the treatment of T2DM.The aim of this article was to provide a thorough review of ...
Kathleen R, Richard +2 more
openaire +2 more sources